My ePortfolio Register   

EMUC 2017: Latest advancements in the treatment and management of prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.11.17
Views: 1635

Prof Karim Fizazi - Institut Gustave Roussy, Paris, France and Dr Cora Sternberg - San Camillo and Forlanini Hospitals, Rome, Italy

Prof Karim Fizazi and Dr Cora Sternberg discuss, at the EMUC 2017 meeting, the latest advancements in the treatment and management of prostate cancer as they look back at key data reported in 2017.

They discuss the key data releases that are have changed the clinical landscape for patient’s with prostate cancer including results from STAMPEDE and CHAARTED which led to the implementation of docetaxel as a therapeutic option earlier in the patient pathway.

The conversation also focuses on the debate as to whether abiraterone in combination with ADT and prednisone or docetaxel in combination with ADT should be treatment of choice for patients with CRPC whilst looking forward to the PEACE1 study which will assess docetaxel and abiraterone being used in combination.

The experts also discuss the treatment of M0 patients, the next generation of therapeutics, including PARP inhibitors and genetic testing as well as the potential use of immunotherapy for the treatment of prostate cancer.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence